Semaglutide

• Stopping GLP-1 drugs could increase heart attack risk for some, study says

  The study showed those considered medically obese showed an even higher risk when they stopped using the drug, than those considered a normal weight.

  Canada

  Nov 11
  
• Hair loss risk goes up on GLP-1 drugs, BMJ study finds

  The BMJ study examined over 50,000 people with Type 2 diabetes taking GLP-1 receptor stimulants, comparing them with patients using other diabetes drugs such as SGLT-2 and DPP-4.

  Health

  Jul 23
  
• Advertisement
• Canada approves 1st generic semaglutide shot for weight loss

  It's the third generic semaglutide product approved by the department, though the first two were authorized for the treatment of Type 2 diabetes in adults.

  Health

  Jun 30
• Advertisement
• Can GLP-1s lower some cancer risks? What new research suggests

  Currently, two generic versions of Ozempic and Wegovy are available for Canadians to purchase for patients who use it to treat diabetes or weight loss for a fraction of the cost.

  Health

  Jun 11
• Generic semaglutide to hit Canadian pharmacies this week at lower cost

  Health Canada approved both Dr. Reddy's and Apotex's generic semaglutide — the active ingredient in brand-name Ozempic and Wegovy — about three weeks ago.

  Health

  May 20
• Canada approves 2nd generic version of semaglutide

  Canada is the first G7 country to authorize generic semaglutide. There are now seven other submissions currently under review for generic semaglutide by different companies.

  Health

  May 1
• With Canada approving 1st generic semaglutide, how will costs compare?

  Manufactured by Dr. Reddy’s Laboratories in India, the injectable medication has been approved for once-a-week treatment of Type 2 diabetes in adults.

  Health

  Apr 29
• Could GLP-1 drugs help your mental health? New study finds a link

  Semaglutide, the active ingredient in GLP-1 drugs, was associated with a lower risk of worsening mental health, a study published in Lancet Psychiatry found.

  Health

  Mar 20
• Advertisement
• Novo Nordisk says generic Ozempic, Wegovy will slow sales in Canada

  Novo Nordisk says the expiration of its patents for some semaglutide GLP-1 drug treatments in markets like Canada will result in more generics and hurt sales.

  Health

  Feb 4
• Advertisement
• Health Canada warns of fake semaglutide drugs, cites ‘product safety’ risks

  Health Canada is warning Canadians of the dangers of buying "fake or unauthorized products" meant to replicate popular GLP-1 drugs such as Ozempic, Rybelsus and Wegovy.

  Consumer

  Jan 22